Harrow, Inc. (HROW) Launches HarrowRx E-Prescribing Platform

Harrow, Inc. (HROW) launched HarrowRx, an e-prescribing and patient-access platform for its ophthalmic portfolio, including VEVYE. The platform is now available to eye care providers through connected EMR systems, extending its partnership with PHIL.

Original reporting

tradingview.com

Published Nov 2, 2026, 2:00 PM UTC

Analysis

AlphAI AI DeskAI-generated

Added to AlphAI Nov 2, 2026, 2:04 PM UTC. Informational, not investment advice.

How this was made

AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.

About AlphAI AI Desk Scoring methodology Report an issue

Harrow, Inc. (HROW) Launches HarrowRx E-Prescribing Platform — source image — Source · tradingview.com

Decision brief

The 30-second read

$HROWNeutralLow

Why it matters

The launch is a strategic move to improve patient access but lacks quantifiable impact at this stage.

Market read

The announcement is a low‑impact corporate development with limited immediate trading relevance.

What to watch

Potential partnership synergies with EMR vendors and the competitive landscape of e‑prescribing solutions.

Relevance 4/10Novelty 3/10Timing: immediate

Background

Harrow, Inc. (NASDAQ:HROW) develops ophthalmic pharmaceuticals and recently expanded its digital offerings.

Company-level read

Ticker impact

AI estimates · verify against primary disclosures

$HROWNeutralHigh confidence

Context

Harrow, Inc. announced the launch of its HarrowRx e‑prescribing platform for its ophthalmic portfolio.

Expected impact

likely limited pressure as the market awaits usage data and revenue impact.

Evidence & confidence

Without disclosed prescription volumes or financial guidance, the announcement alone is unlikely to move the stock significantly.

Market effects

Sector

minor, limited to digital health tools within ophthalmology.

Regional

none

Global

none

Counterpoint

What could challenge this read

If the platform quickly gains provider adoption, it could accelerate Harrow's revenue growth beyond expectations.

Key entities

company
Harrow, Inc.
US‑listed ophthalmic drug developer.
partner
PHIL
Existing partner referenced in the announcement.

Read at source ← All news

$HROWMed

Harrow Closes Acquisition of Tyrvaya, a Dry Eye Disease Treatment From Viatris Inc.

Harrow (HROW) completed its acquisition of Tyrvaya, a dry eye treatment, from Viatris. Harrow paid $30M upfront, with up to $70M in milestones. Tyrvaya is FDA-approved and complements Harrow's existing dry eye therapy, Vevye. Harrow expects Tyrvaya to generate over $30M in 2027 revenue.

visionmonday.comOct 6

$HROWHigh

HARROW, INC. (HROW): Completion of Acquisition or Disposition of Assets

HARROW, INC. (HROW) filed an SEC Form 8-K — Completion of Acquisition or Disposition of Assets. Exhibit 99.1 Harrow Closes Acquisition of TYRVAYA® First and Only FDA-Approved Nasal Spray for Dry Eye Disease Adds a Differentiated, Drop-Free Treatment Option to Harrow’s Growing Ocular Surface Franchise NASHVILLE, Tenn., October 5, 2026 — Harrow (Nasdaq: HROW), a leading provi

SEC EDGAR 8-KOct 5

$HROWHigh

Harrow Closes Acquisition of TYRVAYA®

Harrow (HROW) completed its $30M acquisition of TYRVAYA nasal spray from Viatris, with up to $70M in milestone payments. TYRVAYA, approved for dry eye disease, complements Harrow's VEVYE product. Harrow expects $30M+ revenue from TYRVAYA in 2027, with 40 Viatris employees joining its team.

globenewswire.comOct 5

$HROWLow

Harrow (HROW) Could Be 44% Undervalued After Accounting Leadership Change

Harrow (HROW) announced the departure of its Chief Accounting Officer, with the CFO taking over the role. The company's shares closed at $38.54, with mixed short-term momentum. Analysts suggest Harrow may be undervalued by 44%, citing strong growth potential in its ophthalmic drugs.

simplywall.stSep 6

$HROWLow

Harrow CFO Boll Adds Principal Accounting Officer Role After Pollard Exit – Minichart

Harrow, Inc. (HROW) announced Randall E. Pollard's departure as Chief Accounting Officer. Andrew R. Boll, the CFO, will also serve as principal accounting officer without additional compensation. No reason was given for Pollard's exit.

minichart.com.sgSep 5

$HROWMedAI 8/10

Harrow (HROW) Reported Positive IHEEZO Study Results In Intravitreal Injections

Harrow (HROW) announced positive clinical study results for its IHEEZO ophthalmic gel, showing reduced patient discomfort during intravitreal injections. The study is relevant for Harrow's focus on specialty eye care and may impact its revenue mix. Investors will watch for real-world adoption in retina practices.

simplywall.stAug 25